PGIM Jennison Health Sciences Fund highlighted stocks like Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), in the second quarter ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue ...

Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following re ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a 7% quarter-over-quarter growth in commercial development for its product, with 84,500 vials shipped. The company achieved a significant ...

In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $43.00. The company’s shares ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today. The company’s shares closed yesterday at $27.71. According to TipRanks ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) increased during the last reporting period, rising from 15.26M to 21.09M. This put 23.91% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...